Nab paclitaxel Clinical Trials

117 actively recruiting trials across 36 locations

▼ -1 trial since August 2026

Also known as: ABI 007, ABI 007, ABI-007, ABI-007, Abraxane, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound, ABI-007, ABI007, ABRAXANE, PAZENIR +24 more

Pipeline

Phase 1: 14Phase 2: 56Phase 3: 24Phase 4: 2Phase 1/2: 13Phase 2/3: 6

Top Sponsors

Fudan University7
Merck Sharp & Dohme LLC6
Tianjin Medical University Cancer Institute and Hospital4
Revolution Medicines, Inc.4
National Cancer Institute (NCI)4

Indications

Cancer117
Breast Cancer30
Lung Cancer24
Pancreatic Cancer12
Non Small Cell Lung Cancer11

Other60 trials

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Phase 2

A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer

Phase 3

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Phase 2

A Study for the Adjuvant Treatment of Breast Cancer

Phase 4

A Study for the Neoadjuvant Treatment of Breast Cancer

Phase 4

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Phase 2

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Phase 3

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Phase 1

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase 3

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Phase 3

AB122 Platform Study

Phase 1

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Phase 2

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Phase 2/3

Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Phase 2

Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC

Phase 2

Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma

Phase 1

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Phase 2

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Phase 3

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer

Phase 2

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Phase 3

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer

Phase 2

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Phase 1/2

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Phase 2

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Phase 2

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Phase 2

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Phase 1

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

Phase 2

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Phase 2

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

Phase 1

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Phase 2

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Phase 2

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Phase 2

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Phase 2

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Phase 2

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1

Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Phase 2

Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

Phase 2

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

N/A

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Phase 2

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Phase 2

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3

Second-line Immunotherapy for ES-SCLC

N/A

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1/2

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1/2

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Phase 3

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Phase 2

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Phase 2

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Phase 2

Duarte, California4 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope - Duarte

Phase 1/2

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

City of Hope Medical Center

Phase 1

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

City of Hope Medical Center

Phase 1

Boston, Massachusetts3 trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Massachusetts General Hospital

Phase 1

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Boston Medical Center

Phase 1

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Houston, Texas3 trials

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

MD Anderson Cancer Center

Phase 2

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

M D Anderson Cancer Center

Phase 2

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M D Anderson Cancer Center

Phase 1

Daphne, Alabama2 trials

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Southern Cancer Center (SCC) ( Site 8000)

Phase 3

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site

Phase 3

Anchorage, Alaska2 trials

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Local Institution - 0119

Phase 2/3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Anchorage Associates in Radiation Medicine

Phase 3

Chandler, Arizona2 trials

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Ironwood Cancer & Research Centers ( Site 0066)

Phase 3

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Ironwood Cancer and Research Centers

Phase 1/2

Gilbert, Arizona2 trials

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center

Phase 1/2

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona2 trials

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 1/2

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Mayo Clinic - Scottsdale

Phase 3

Scottsdale, Arizona2 trials

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Mayo Clinic in Arizona

Phase 2

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Site 02

Phase 2

Tucson, Arizona2 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site

Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

The University of Arizona Cancer Center-North Campus

Phase 3

Hot Springs, Arkansas2 trials

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Local Institution - 0303

Phase 2/3

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Genesis Cancer and Blood Institute (SCRI)

Phase 2/3

Loma Linda, California2 trials

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

VA Loma Linda Healthcare System

Phase 3

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Loma Linda University Health

Phase 2

Los Angeles, California2 trials

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

START Los Angeles, LLC

Phase 1/2

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

The Angeles Clinic and Research Institute - West Los Angeles Office

Phase 1

Tampa, Florida2 trials

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Moffitt Cancer Center ( Site 0021)

Phase 2

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Moffitt Cancer Center

Phase 3

Atlanta, Georgia2 trials

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Emory University Hospital/Winship Cancer Institute

Phase 2

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Emory University Hospital/Winship Cancer Institute

Phase 2

New York, New York2 trials

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Columbia University Irving Medical Center

Phase 2

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

Columbia University Medical Center

Phase 2

Winston-Salem, North Carolina2 trials

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Birmingham, Alabama1 trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Mobile, Alabama1 trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

USA Mitchell Cancer Institute ( Site 0090)

Phase 3

Fayetteville, Arkansas1 trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Highlands Oncology Group - Fayetteville

Phase 3

Little Rock, Arkansas1 trial

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

CARTI Cancer Center ( Site 0006)

Phase 3

El Segundo, California1 trial

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Chan Soon-Shiong Institute for Medicine

Phase 1/2

Orange, California1 trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

San Francisco, California1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0096

Phase 2

Santa Monica, California1 trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

UCLA

Phase 1

Chicago, Illinois1 trial

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

University of Illinois

Phase 2

Lexington, Kentucky1 trial

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

University of Kentucky ( Site 0019)

Phase 2

Baltimore, Maryland1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Johns Hopkins Hospital

Phase 1/2

Bethesda, Maryland1 trial

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute Developmental Therapeutics Clinic

Phase 2

Clarkston, Michigan1 trial

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Karmanos Cancer Institute at McLaren Clarkston

Phase 2

Rochester, Minnesota1 trial

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Mayo Clinic in Rochester

Phase 2

St Louis, Missouri1 trial

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2

Chapel Hill, North Carolina1 trial

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 1/2

Columbus, Ohio1 trial

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Ohio State University Comprehensive Cancer Center

Phase 2

Philadelphia, Pennsylvania1 trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Nashville, Tennessee1 trial

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.